Neuroenergy Ventures, Inc.

Other

Neuroenerygy Ventures, Inc.

Sami Hashim

Joseph C Rongione

Jenifer Heydinger Galante

Joanna Jusis

A method of use of Glyceryl Tris (Beta-hydroxybutyrate) in the minimization, reduction, or prevention of neuronal deficit and/or neuronal cell death with respect to follow-on neuronal transient ischemic attacks (NTIAs) in subjects who have had (or in subjects exhibiting symptomology of having had) at least one prior NTIA.

Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks

A method of treatment of mild to moderate non-penetrating closed traumatic brain injury and mild to moderate TBI due to surgical intervention using 3-hydroxybutyate glycerides is disclosed.

Glyceryl 3-hydroxybutyrates for traumatic brain injury

A method of management of migraine symptom reduction and/or management and/or prophylaxis is disclosed using 3-hydroxybutyrate glycerides is disclosed.

Glyceryl 3-hydroxybutyrates for migraine symptom management

Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition.

Growing community of inventors

Dobbs Ferry, NY, United States of America

Sami Hashim